Clinical Study I:

Repeated Low Doses of Ketamine & Psilocybin on Parkinson’s Disease

Investigator-Sponsored Study Agreement
Maastricht University of the Netherlands

Market Opportunity

Parkinson’s Disease

  • 1.2M Americans expected to have Parkinson’s Disease by 2030
  • Parkinson’s growing by 50% in Americans between the ages of 30 and 64
  • Global market for Parkinson’s drugs expected to reach $8.4billion by 2026

Technology

  • Repeated low doses of psilocybin and ketamine

Applications

  • Better awareness of cognitive and emotional dysfunctions in Parkinson’s disease
  • Gain understanding of repeated low doses of psilocybin and ketamine and their mechanism of action

Get more information on Silo Pharma. Sign up for email alerts online.

SIGN UP